Machine learning methods, databases and tools for drug combination prediction
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Combination therapy has shown an obvious efficacy on complex diseases and can greatly reduce the development of drug resistance. However, even with high-throughput screens, experimental methods are insufficient to explore novel drug combinations. In order to reduce the search space of drug combinations, there is an urgent need to develop more efficient computational methods to predict novel drug combinations. In recent decades, more and more machine learning (ML) algorithms have been applied to improve the predictive performance. The object of this study is to introduce and discuss the recent applications of ML methods and the widely used databases in drug combination prediction. In this study, we first describe the concept and controversy of synergism between drug combinations. Then, we investigate various publicly available data resources and tools for prediction tasks. Next, ML methods including classic ML and deep learning methods applied in drug combination prediction are introduced. Finally, we summarize the challenges to ML methods in prediction tasks and provide a discussion on future work.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“machine learning models can predict patients’ responses to specific drug combinations on the basis of their individual characteristics, such as mutation profiles and protein expression profiles, thereby providing a basis for personalized treatment.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [490]
In the citing paper
“we can evaluate the impact of different drug combinations on the p53 signaling pathway via machine learning models, such as stochastic gradient boosting (SGB) or deep learning, to optimize combination therapies.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [490]
In the citing paper
“We can identify key targets and pathways that interact with the p53 signaling pathway through systems biology methods, such as network analysis and pathway enrichment analysis.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [490]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
XGBoost: A Scalable Tree Boosting System
Chen, T., & Guestrin, C. (2016) · Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining · doi:10.1145/2939672.2939785 · Cited by 54,569
A Unified Approach to Interpreting Model Predictions
Lundberg, S., & Lee, S.-I. (2017) · arXiv · doi:10.48550/arxiv.1705.07874 · Cited by 23,707
KEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
UniProt: a worldwide hub of protein knowledge
The UniProt Consortium (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1049 · Cited by 7,698
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Gradient boosting machines, a tutorial
Natekin, A., & Knoll, A. (2013) · Frontiers in Neurorobotics · doi:10.3389/fnbot.2013.00021 · Cited by 3,887 · cited 1×
“Gradient boosting method [109] is a popular method in boosting-based methods.”
MethodApplications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Research works printed but not linked: 128
- Jia, 2009, Mechanisms of drug combinations: interaction and network perspectives, Nat Rev Drug Discov, 8, 111, 10.1038/nrd2683 · DOI · Paper page
- Lopez, 2017, Combine and conquer: challenges for targeted therapy combinations in early phase trials, Nature Nat Rev Clin Oncol, 14, 57, 10.1038/nrclinonc.2016.96 · DOI · Paper page
- Pang, 2014, Combinatorial therapy discovery using mixed integer linear programming, Bioinformatics, 30, 1456, 10.1093/bioinformatics/btu046 · DOI
- Hopkins, 2008, Network pharmacology: the next paradigm in drug discovery, Nat Chem Biol, 4, 682, 10.1038/nchembio.118 · DOI · Paper page
- Ramsay, 2018, A perspective on multi-target drug discovery and design for complex diseases, Clin Transl Med, 7, 3, 10.1186/s40169-017-0181-2 · DOI · Paper page
- Sheng, 2017, Advances in computational approaches in identifying synergistic drug combinations, Brief Bioinform, 19, 1172
- Narayan, 2020, A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities, Nat Commun, 11, 2935, 10.1038/s41467-020-16735-2 · DOI
- Housman, 2014, Drug resistance in cancer: an overview, Cancer, 6, 1769, 10.3390/cancers6031769 · DOI · Paper page
- Chang, 2001, Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters, Science, 293, 1793, 10.1126/science.293.5536.1793 · DOI · Paper page
- Toy, 2013, ESR1 ligand-binding domain mutations in hormone-resistant breast cancer, Nat Genet, 45, 1439, 10.1038/ng.2822 · DOI · Paper page
- Lovly, 2014, Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies, Clin Cancer Res, 20, 2249, 10.1158/1078-0432.CCR-13-1610 · DOI · Paper page
- Madani Tonekaboni, 2018, Predictive approaches for drug combination discovery in cancer, Brief Bioinform, 19, 263, 10.1093/bib/bbw104 · DOI · Paper page
- Ianevski, 2019, Prediction of drug combination effects with a minimal set of experiments, Nat Mach Intell, 1, 568, 10.1038/s42256-019-0122-4 · DOI · Paper page
- Preuer, 2018, Deep synergy: predicting anti-cancer drug synergy with deep learning, Bioinformatics, 34, 1538, 10.1093/bioinformatics/btx806 · DOI · Paper page
- Leh, Aacute, R J, 2, 2009, Synergistic drug combinations tend to improve therapeutically relevant selectivity, Nat Biotechnol, 27, 659, 10.1038/nbt.1549 · DOI · Paper page
- Tan, 2012, Systematic identification of synergistic drug pairs targeting HIV, Nat Biotechnol, 30, 1125, 10.1038/nbt.2391 · DOI · Paper page
- Zhao, 2011, Prediction of drug combinations by integrating molecular and pharmacological data, PLoS Comput Biol, 7, 10.1371/journal.pcbi.1002323 · DOI · Paper page
- Bleicher, 2003, Hit and lead generation: beyond high-throughput screening, Nat Rev Drug Discov, 2, 369, 10.1038/nrd1086 · DOI · Paper page
- Morris, 2016, Systematic analysis of quantitative logic model ensembles predicts drug combination effects on cell signaling networks, CPT Pharmacometrics Syst Pharmacol, 5, 544, 10.1002/psp4.12104 · DOI
- Feala, 2010, Systems approaches and algorithms for discovery of combinatorial therapies, Wiley Interdiscip Rev Syst Biol Med, 2, 181, 10.1002/wsbm.51 · DOI · Paper page
- Sun, 2016, Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination, Oncotarget, 7, 63995, 10.18632/oncotarget.11745 · DOI · Paper page
- Lee, 2012, CDA: combinatorial drug discovery using transcriptional response modules, Plos One, 7, 10.1371/journal.pone.0042573 · DOI
- Zinner, 2009, Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells, Mol Cancer Ther, 8, 521, 10.1158/1535-7163.MCT-08-0937 · DOI
- Talevi, 2020, Machine learning in drug discovery and development part 1: a primer, CPT Pharmacometrics Syst Pharmacol, 9, 129, 10.1002/psp4.12491 · DOI · Paper page
- Tsigelny, 2019, Artificial intelligence in drug combination therapy, Brief Bioinform, 20, 1434, 10.1093/bib/bby004 · DOI · Paper page
- Menden, 2019, Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen, Nat Commun, 10, 10.1038/s41467-019-09799-2 · DOI · Paper page
- Sidorov, 2019, Predicting synergism of cancer drug combinations using NCI-ALMANAC data, Front Chem, 7, 10.3389/fchem.2019.00509 · DOI · Paper page
- Huang, 2014, Drug combo ranker: drug combination discovery based on target network analysis, Bioinformatics, 30, i228, 10.1093/bioinformatics/btu278 · DOI · Paper page
- Sun, 2015, Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer, Nat Commun, 6, 10.1038/ncomms9481 · DOI · Paper page
- Chen, 2016, NLLSS: predicting synergistic drug combinations based on semi-supervised learning, PLoS Comput Biol, 12, 10.1371/journal.pcbi.1004975 · DOI · Paper page
- Zagidullin, 2019, Drug comb: an integrative cancer drug combination data portal, Nucleic Acids Res, 47, W43, 10.1093/nar/gkz337 · DOI · Paper page
- Tang, 2015, What is synergy? The Saariselka agreement revisited, Front Pharmacol, 6, 10.3389/fphar.2015.00181 · DOI · Paper page
- Chou, 2008, Preclinical versus clinical drug combination studies, Leuk Lymphoma, 49, 2059, 10.1080/10428190802353591 · DOI · Paper page
- Loewe, 1953, The problem of synergism and antagonism of combined drugs, Arzneimittelforschung, 3, 285
- Shafer, 2008, Additivity versus synergy: a theoretical analysis of implications for anesthetic mechanisms, Anesth Anal, 107, 507, 10.1213/ane.0b013e31817b7140 · DOI
- Laskey, 2014, A mechanistic theory to explain the efficacy of antiretroviral therapy, Nat Rev Microbiol, 12, 772, 10.1038/nrmicro3351 · DOI
- Chevereau, 2015, Systematic discovery of drug interaction mechanisms, Mol Syst Biol, 11, 807, 10.15252/msb.20156098 · DOI · Paper page
- Tallarida, 2006, An overview of drug combination analysis with isobolograms, J Pharmacol Exp Ther, 319, 1, 10.1124/jpet.106.104117 · DOI · Paper page
- Greco, 1995, The search for synergy: a critical review from a response surface perspective, Pharmacol Rev, 47, 331
- Chou, 1983, Analysis of combined drug effects: a new look at a very old problem, Trends Pharmacol Sci, 4, 450, 10.1016/0165-6147(83)90490-X · DOI · Paper page
- Zheng, 2021, Drug comb update: a more comprehensive drug sensitivity data repository and analysis portal, Nucleic Acids Res, 1
- Hancock, 2020, CatBoost for big data: an interdisciplinary review, J Big Data, 7, 94, 10.1186/s40537-020-00369-8 · DOI · Paper page
- Liu, 2019, DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy, Nucleic Acids Res, 48, D871
- Giordano, 2008, From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage, Curr Med Chem, 15, 422, 10.2174/092986708783503212 · DOI · Paper page
- Haibe-Kains, 2020, SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology, Nucleic Acids Res, 48, W494, 10.1093/nar/gkaa421 · DOI
- Chen, 2014, ASDCD: antifungal synergistic drug combination database, PLoS One, 9, 10.1371/journal.pone.0086499 · DOI · Paper page
- Liu, 2010, DCDB: drug combination database, Bioinformatics, 26, 587, 10.1093/bioinformatics/btp697 · DOI · Paper page
- Liu, 2014, DCDB 2.0: a major update of the drug combination database, Database, 2014, 10.1093/database/bau124 · DOI
- Zhu, 2018, Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics, Nucleic Acids Res, 46, D1121, 10.1093/nar/gkx1076 · DOI · Paper page
- Masoudi-Sobhanzadeh, 2019, DrugR+: a comprehensive relational database for drug repurposing, combination therapy, and replacement therapy, Comput Biol Med, 109, 254, 10.1016/j.compbiomed.2019.05.006 · DOI · Paper page
- He, 1711, Methods for high-throughput drug combination screening and synergy scoring, Methods Mol Biol, 2018, 351
- Ianevski, 2017, SynergyFinder: a web application for analyzing drug combination dose–response matrix data, Bioinformatics, 33, 2413, 10.1093/bioinformatics/btx162 · DOI · Paper page
- Aittokallio, 2020, SynergyFinder 2.0: visual analytics of multi-drug combination synergies, Nucleic Acids Res, 48, W488, 10.1093/nar/gkaa216 · DOI · Paper page
- Wooten, 2021, Synergy: a python library for calculating, analyzing and visualizing drug combination synergy, Bioinformatics, 37, 1473, 10.1093/bioinformatics/btaa826 · DOI · Paper page
- Chou, 2007, The mass-action law-based new computer software, CompuSyn, for automated simulation of synergism and antagonism in drug combination studies, Cancer Res, 67, 637
- Di Veroli, 2016, Combenefit: an interactive platform for the analysis and visualization of drug combinations, Bioinformatics, 32, 2866, 10.1093/bioinformatics/btw230 · DOI · Paper page
- Noble, 2006, What is a support vector machine?, Nat Biotechnol, 24, 1565, 10.1038/nbt1206-1565 · DOI · Paper page
- Safavian, 1991, A survey of decision tree classifier methodology, IEEE Trans Syst Man Cybern, 21, 660, 10.1109/21.97458 · DOI · Paper page
- Schmidhuber, 2015, Deep learning in neural networks: an overview, Neural Netw, 61, 85, 10.1016/j.neunet.2014.09.003 · DOI · Paper page
- Yuming, 2015, Deep belief networks and deep learning, 10.1109/ICAIOT.2015.7111524 · DOI · Paper page
- Kramer, 1991, Nonlinear principal component analysis using autoassociative neural networks, AIChE J, 37, 233, 10.1002/aic.690370209 · DOI · Paper page
- Janizek, 2018, Explainable machine learning prediction of synergistic drug combinations for precision cancer medicine, bioRxiv
- Gayvert, 2017, A computational approach for identifying synergistic drug combinations, PLoS Comput Biol, 13, 10.1371/journal.pcbi.1005308 · DOI · Paper page
- Xu, 2017, PDC-SGB: prediction of effective drug combinations using a stochastic gradient boosting algorithm, J Theor Biol, 417, 1, 10.1016/j.jtbi.2017.01.019 · DOI
- Rifaioglu, 2019, Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases, Brief Bioinform, 20, 1878, 10.1093/bib/bby061 · DOI · Paper page
- Jiao, 2016, Performance measures in evaluating machine learning based bioinformatics predictors for classifications, Quant Biol, 4, 320, 10.1007/s40484-016-0081-2 · DOI · Paper page
- Rendle, 2010, Factorization machines, 10.1109/ICDM.2010.127 · DOI · Paper page
- Friedman, 2002, Stochastic gradient boosting, Comput Stat Data Anal, 38, 367, 10.1016/S0167-9473(01)00065-2 · DOI · Paper page
- Webb, 2010, Naïve Bayes. Encyclopedia of Machine Learning, 713
- Wright, 1995, Logistic Regression. Reading and Understanding Multivariate Statistics, 217
- Sun, 2014, A hadoop-based method to predict potential effective drug combination, Biomed Res Int, 2014, 196858, 10.1155/2014/196858 · DOI
- Li, 2020, A machine learning method for drug combination prediction, Front Genet, 11, 1000, 10.3389/fgene.2020.01000 · DOI
- Pivetta, 2013, Development and validation of a general approach to predict and quantify the synergism of anti-cancer drugs using experimental design and artificial neural networks, Talanta, 115, 84, 10.1016/j.talanta.2013.04.031 · DOI
- Julkunen, 2020, Leveraging multiway interactions for systematic prediction of pre-clinical drug combination effects, Nat Commun, 11, 10.1038/s41467-020-19950-z · DOI · Paper page
- Polikar, 2006, Ensemble based systems in decision making, IEEE Circuits Syst Mag, 6, 21, 10.1109/MCAS.2006.1688199 · DOI · Paper page
- Breiman, 1996, Bagging predictors, Machine Learning, 24, 123, 10.1007/BF00058655 · DOI · Paper page
- Wildenhain, 2015, Prediction of synergism from chemical-genetic interactions by machine learning, Cell Syst, 1, 383, 10.1016/j.cels.2015.12.003 · DOI · Paper page
- Chen, 2013, Prediction of effective drug combinations by chemical interaction, protein interaction and target enrichment of KEGG pathways, Biomed Res Int, 2013, 1, 10.1155/2013/839761 · DOI
- Kalantarmotamedi, 2018, A systematic and prospectively validated approach for identifying synergistic drug combinations against malaria, Malar J, 17, 160, 10.1186/s12936-018-2294-5 · DOI
- Li, 2017, Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles, Artif Intell Med, 83, 35, 10.1016/j.artmed.2017.05.008 · DOI
- Ma, 2019, Transcriptomic signatures predict regulators of drug synergy and clinical regimen efficacy against tuberculosis, MBio, 10, 10.1128/mBio.02627-19 · DOI
- He, 2018, Patient-customized drug combination prediction and testing for T-cell prolymphocytic leukemia patients, Cancer Res, 78, 2407, 10.1158/0008-5472.CAN-17-3644 · DOI
- Lo, 2019, Machine learning with statistical imputation for predicting drug approval, Harvard Data Sci Rev, 1
- Degenhardt, 2019, Evaluation of variable selection methods for random forests and omics data sets, Brief Bioinform, 20, 492, 10.1093/bib/bbx124 · DOI · Paper page
- Verikas, 2016, Electromyographic patterns during golf swing: activation sequence profiling and prediction of shot effectiveness, Sensors, 16, 10.3390/s16040592 · DOI
- Zhang, 2017, Predicting potential drug-drug interactions by integrating chemical, biological, phenotypic and network data, BMC Bioinformatics, 18, 18, 10.1186/s12859-016-1415-9 · DOI · Paper page
- Tang, 2020, Indicator regularized non-negative matrix factorization method-based drug repurposing for COVID-19, Front Immunol, 11, 603615, 10.3389/fimmu.2020.603615 · DOI
- Shi, 2019, Predicting combinative drug pairs via multiple classifier system with positive samples only, Comput Methods Programs Biomed, 168, 1, 10.1016/j.cmpb.2018.11.002 · DOI
- Baptista, 2021, Deep learning for drug response prediction in cancer, Brief Bioinform, 22, 360, 10.1093/bib/bbz171 · DOI · Paper page
- Muzio, 2021, Biological network analysis with deep learning, Brief Bioinform, 22, 1515, 10.1093/bib/bbaa257 · DOI · Paper page
- Kuru, 2021, MatchMaker: a deep learning framework for drug synergy prediction, IEEE/ACM Trans Comput Biol Bioinform, 1, 10.1109/TCBB.2021.3086702 · DOI · Paper page
- Larochelle, 2012, Learning algorithms for the classification restricted Boltzmann machine, J Mach Learn Res, 13, 643
- Hinton, 2006, A fast learning algorithm for deep belief nets, Neural Comput, 18, 1527, 10.1162/neco.2006.18.7.1527 · DOI · Paper page
- Chen, 2018, Predict effective drug combination by deep belief network and ontology fingerprints, J Biomed Inform, 85, 149, 10.1016/j.jbi.2018.07.024 · DOI · Paper page
- Zhang, 2021, Synergistic drug combination prediction by integrating multiomics data in deep learning models, Methods Mol Biol, 2194, 223, 10.1007/978-1-0716-0849-4_12 · DOI · Paper page
- Kipf, 2016, Semi-Supervised Classification with Graph Convolutional Networks
- Jiang, 2020, Deep graph embedding for prioritizing synergistic anticancer drug combinations, Comput Struct Biotechnol J, 18, 427, 10.1016/j.csbj.2020.02.006 · DOI · Paper page
- Boven, 2005, Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule, Br J Cancer, 92, 1636, 10.1038/sj.bjc.6602553 · doi:10.1038/sj.bjc.6602553
- Malyutina, 2019, Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer, PLoS Comput Biol, 15, 10.1371/journal.pcbi.1006752 · DOI · Paper page
- Richards, 2020, Drug antagonism and single-agent dominance result from differences in death kinetics, Nat Chem Biol, 16, 791, 10.1038/s41589-020-0510-4 · DOI
- Guan, 2019, Anticancer drug response prediction in cell lines using weighted graph regularized matrix factorization, Mol Ther Nucleic Acids, 17, 164, 10.1016/j.omtn.2019.05.017 · DOI
- Liu, 2018, Anti-cancer drug response prediction using neighbor-based collaborative filtering with global effect removal, Mol Ther - Nucleic Acids, 13, 303, 10.1016/j.omtn.2018.09.011 · DOI
- Yang, 2008, Finding multiple target optimal intervention in disease-related molecular network, Mol Syst Biol, 4, 228, 10.1038/msb.2008.60 · DOI · Paper page
- Cheng, 2019, Network-based prediction of drug combinations, Nat Commun, 10, 1197, 10.1038/s41467-019-09186-x · DOI · Paper page
- Tang, 2013, Target inhibition networks: predicting selective combinations of Druggable targets to block cancer survival pathways, PLoS Comput Biol, 9, 10.1371/journal.pcbi.1003226 · DOI · Paper page
- Hu, 2019, Prediction of synergistic drug combinations by learning from deep representations of multiple networks, Stud Health Technol Inform, 264, 1482
- Huang, 2014, Systematic prediction of drug combinations based on clinical side-effects, Sci Rep, 4, 7160, 10.1038/srep07160 · DOI · Paper page
- Shi, 2017, Predicting combinative drug pairs towards realistic screening via integrating heterogeneous features, BMC Bioinformatics, 18, 409, 10.1186/s12859-017-1818-2 · DOI
- Ji, 2019, Five-feature model for developing the classifier for synergistic vs. antagonistic drug combinations built by XGBoost, Front Genet, 10, 600, 10.3389/fgene.2019.00600 · DOI
- Liu, 2019, Predicting effective drug combinations using gradient tree boosting based on features extracted from drug-protein heterogeneous network, BMC Bioinformatics, 20, 645, 10.1186/s12859-019-3288-1 · DOI · Paper page
- Zhang, 2019, Synergistic drug combinations prediction by integrating pharmacological data, Synth Syst Biotechnol, 4, 67, 10.1016/j.synbio.2018.10.002 · DOI
- Szklarczyk, 2016, STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data, Nucleic Acids Res, 44, D380, 10.1093/nar/gkv1277 · DOI · Paper page
- Kanehisa, 2006, From genomics to chemical genomics: new developments in KEGG, Nucleic Acids Res, 34, D354, 10.1093/nar/gkj102 · DOI · Paper page
- Kanehisa, 2008, KEGG for linking genomes to life and the environment, Nucleic Acids Res, 36, D480
- Kuhn, 2016, The SIDER database of drugs and side effects, Nucleic Acids Res, 44, D1075, 10.1093/nar/gkv1075 · DOI · Paper page
- Kim, 2019, PubChem 2019 update: improved access to chemical data, Nucleic Acids Res, 47, D1102, 10.1093/nar/gky1033 · DOI · Paper page
- Oughtred, 2019, The BioGRID interaction database: 2019 update, Nucleic Acids Res, 47, D529, 10.1093/nar/gky1079 · DOI · Paper page
- Keshava Prasad, 2009, Human protein reference database--2009 update, Nucleic Acids Res, 37, D767, 10.1093/nar/gkn892 · DOI · Paper page
- Gaulton, 2017, The ChEMBL database in 2017, Nucleic Acids Res, 45, D945, 10.1093/nar/gkw1074 · DOI · Paper page
- Tang, 2018, Drug target commons: a community effort to build a consensus knowledge base for drug-target interactions, Cell Chem Biol, 25, 224, 10.1016/j.chembiol.2017.11.009 · DOI · Paper page
- Berenstein, 2020, TDR targets 6: driving drug discovery for human pathogens through intensive chemogenomic data integration, Nucleic Acids Res, 48, D992
- Pawson, 2014, The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands, Nucleic Acids Res, 42, D1098, 10.1093/nar/gkt1143 · DOI · Paper page
- Kumar, 2013, CancerDR: cancer drug resistance database, Sci Rep, 3, 1445, 10.1038/srep01445 · DOI · Paper page
- Liu, 2007, BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities, Nucleic Acids Res, 35, D198, 10.1093/nar/gkl999 · DOI · Paper page
- He, 2015, TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples, Bioinformatics, 31, 1866, 10.1093/bioinformatics/btv067 · DOI
- Li, 2015, Large-scale exploration and analysis of drug combinations, Bioinformatics, 31, 10.1093/bioinformatics/btv080 · DOI · Paper page
- Held, 2013, Genotype-selective combination therapies for melanoma identified by high-throughput drug screening, Cancer Discov, 3, 52, 10.1158/2159-8290.CD-12-0408 · DOI · Paper page
- Mott, 2015, High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations, Sci Rep, 5, 13891, 10.1038/srep13891 · DOI · Paper page
Cited by
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Wu, L., Wen, Y., Leng, D., Zhang, Q., Dai, C., Wang, Z., Liu, Z., Yan, B., Zhang, Y., Wang, J., He, S., & Bo, X.
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-09-02
- Volume
- 23
- Issue
- 1
- ISSN
- 1467-5463
- 1477-4054
- Cited by
- 126
- References
- 34
- Language
- en
- Funders
- National Natural Science Foundation of China (62103436)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Machine learning methods, databases and tools for drug combination prediction. https://app.cochat.ai/papers/10.1093/bib/bbab355
- The paper
- Wu, L., Wen, Y., Leng, D., Zhang, Q., Dai, C., Wang, Z., Liu, Z., Yan, B., Zhang, Y., Wang, J., He, S., & Bo, X. (2022). Machine learning methods, databases and tools for drug combination prediction. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbab355
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.